Invesco Ltd. Has $1.83 Billion Holdings in CVS Health Corporation $CVS

Invesco Ltd. grew its stake in CVS Health Corporation (NYSE:CVS) by 3.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,293,058 shares of the pharmacy operator’s stock after acquiring an additional 760,579 shares during the period. Invesco Ltd.’s holdings in CVS Health were worth $1,831,454,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. SOA Wealth Advisors LLC. increased its holdings in shares of CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 131 shares in the last quarter. Alteri Wealth LLC lifted its holdings in CVS Health by 3.2% during the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after buying an additional 131 shares in the last quarter. Holistic Financial Partners boosted its position in CVS Health by 4.1% in the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after buying an additional 133 shares during the last quarter. Symmetry Partners LLC boosted its position in CVS Health by 2.5% in the 3rd quarter. Symmetry Partners LLC now owns 5,826 shares of the pharmacy operator’s stock valued at $439,000 after buying an additional 141 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its stake in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 142 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Up 0.5%

Shares of NYSE CVS opened at $76.10 on Friday. CVS Health Corporation has a twelve month low of $58.35 and a twelve month high of $85.15. The stock has a market cap of $96.81 billion, a price-to-earnings ratio of 55.14, a P/E/G ratio of 0.79 and a beta of 0.49. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The company’s fifty day moving average is $78.25 and its 200-day moving average is $77.71.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $105.69 billion during the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Thursday, January 22nd were given a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is currently 192.75%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS from “market perform” to “outperform” and raised its price target to $94, increasing analyst conviction and suggesting ~23% upside vs. current levels. Read More.
• Positive Sentiment: CVS announced an AI-powered consumer health platform — a strategic push into digital care and personalization that could support margin expansion and higher patient engagement over time. Product rollout increases growth narrative beyond traditional retail/pharmacy. Read More.
• Positive Sentiment: Coverage of CVS investing in advanced consumer tech (“agentic twins”) signals ongoing R&D and digital transformation that investors often reward if it drives stickier customer relationships and services revenue. Read More.
• Neutral Sentiment: North Carolina’s health-plan contracting dynamics may trigger a competitive bidding environment for Aetna and CVS; this could create upside from new wins but also pressure on pricing depending on outcomes. Monitor contract renewals and win rates. Read More.
• Neutral Sentiment: Health-care sector weakness is a short-term headwind: the NYSE Health Care Index was modestly lower recently, which can pressure CVS alongside peers even when company-specific news is mixed. Read More.
• Neutral Sentiment: Market commentators note CVS is modestly down since its last earnings report — investors should focus on FY2026 guidance vs. consensus and upcoming catalysts that could re-rate the stock. Read More.
• Negative Sentiment: DOJ settlement: Aetna (CVS’s unit) agreed to a $117.7M settlement over alleged Medicare Advantage coding issues. While not crippling to cash flows, it is a near-term legal expense and adds regulatory scrutiny for Aetna’s Medicare business. Read More.
• Negative Sentiment: CVS says it may close 100+ Tennessee pharmacies in response to state PBM-related legislation — a politically charged dispute that could disrupt retail access, revenue in affected markets, and raise execution/PR risk if closures proceed. Read More.

Analysts Set New Price Targets

Several brokerages have recently issued reports on CVS. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and upped their price target for the company from $91.00 to $94.00 in a research note on Thursday. Leerink Partners reiterated an “outperform” rating and issued a $98.00 price objective on shares of CVS Health in a research report on Thursday, March 5th. UBS Group reissued an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Robert W. Baird raised their target price on shares of CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Finally, Wolfe Research lowered their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.